Browsing by Author Mok, Tony

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2015Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsBoyer, Michael; Bennouna, Jaafar; Feng, Jifeng; Geater, Sarayut; Gorbunova, Vera; Hirsh, Vera; Hu, Cheng-Ping; Huang, Yunchao; Kato, Terufumi; Lee, Ki Hyeong; Lee, Kye Young; Lu, Shun; Massey, Dan; Mok, Tony; O'Byrne, Kenneth; Orlov, Sergey; Popat, Sanjay; Schuler, Martin; Sebastian, Martin; Sequist, Lecia; Shahidi, Mehdi; Su, Wu-Chou; Tsai, Chun-Ming; Wu, Yi-long; Yamamoto, Nobuyuki; Yang, James Chic-Hsin; Zazulina, Victoria; Zhou, Caicun; Central Clinical School: MedicineAfatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials, Lancet Oncology, vol.16, 2, 2015,pp 141-151
2016Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Ken J; Park, Keunchil; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial, The Lancet Oncology, vol.17, 5, 2016,pp 577-589
2017Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trialBoyer, Michael; et al, Various; Hirsh, Vera; Lee, Ki Hyeong; Lu, Shun; Mok, Tony; O'Byrne, Kenneth J.; Paz-Ares, Luis; Tan, Eng Huat; Yang, James Chic-Hsin; Zhang, Li; Central Clinical School: MedicineAfatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial, Annals of Oncology, vol.28, 2, 2017,pp 270-277
2017Checkpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-AnalysisGebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Links, Matthew; Man, J; Mok, Tony; Yang, J; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreCheckpoint Inhibitors in Metastatic EGFR-Mutated Non`Small Cell Lung Cancer A Meta-Analysis, Journal of Thoracic Oncology, vol.12, 2, 2017,pp 403-407
2017Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survivalDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Fukuoka, Masahiro; Gralla, Richard J; Inoue, Akira; Mitsudomi, Tetsuya; Mok, Tony; Nakagawa, Kazuhiko; Rosell, Rafael Costa; Thongprasert, Sumitra; Tu, Yu-Kang; Wu, Yi-long; Yang, James; Zhou, Caicun; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival, Journal of the National Cancer Institute, vol.109, 6, 2017,pp 1-13
2012An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinomaBoyer, Michael; Erlichman, Charles; Holen, Kyle; Kim, G P; Mahoney, Michelle; Marshke, Robert; Mok, Tony; Nowak, Anna; Philip, Philip; Picus, Joel; Pitot, Henry; Rubin, Joseph; Szydlo, Daniel; Wright, John J.; Central Clinical School: MedicineAn international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma, Investigational New Drugs, vol.30, 1, 2012,pp 387-394
2006Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.Boyer, Michael; Abratt, R.; Brnabic, Alan J.M.; Han, Ji Youn; Kim, Sang-We; Lee, Jin Soo; Lee, Jung Sin; Mok, Tony; Reece, William H.H.; Tsai, Chun-Ming; Central Clinical School: MedicinePhase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer., Journal of Thoracic Oncology, vol.1,(2),2006,pp 135-140